Litcius/Paper detail

Clinical response and pathway-specific correlates following TIGIT–LAG3 blockade in myeloma: the MyCheckpoint randomized clinical trial

Shambavi Richard, Alexander M. Lesokhin, Barry Paul, Jonathan L. Kaufman, Matthew J. Pianko, Noa Biran, Ravi Vij, Deon B. Doxie, Maryam I. Azeem, Mercedes Martillo, Katie Wozniak, Hearn Jay Cho, Kavita M. Dhodapkar, Madhav V. Dhodapkar

2024Nature Cancer20 citationsDOIOpen Access PDF

Topics & Concepts

TIGITPomalidomideMedicineT cellDexamethasoneImmunologyCancer researchInternal medicineMultiple myelomaImmune systemBortezomibImmune Cell Function and InteractionCAR-T cell therapy researchCancer Immunotherapy and Biomarkers
Clinical response and pathway-specific correlates following TIGIT–LAG3 blockade in myeloma: the MyCheckpoint randomized clinical trial | Litcius